Comparative Pharmacology
Head-to-head clinical analysis: THEOLAIR SR versus XTRELUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOLAIR SR versus XTRELUS.
THEOLAIR-SR vs XTRELUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing cAMP, and antagonizing adenosine receptors.
Selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and lowering blood glucose levels.
Oral: 300-600 mg every 12 hours; sustained-release formulation; adjust based on serum theophylline concentrations (target 5-15 mcg/mL).
XTRELUS (luseogliflozin) 2.5 mg orally once daily, increased to 5 mg once daily if needed.
None Documented
None Documented
Adults: 8 hours (range 5-12). Children: 3.5 hours (range 1-8). Smokers: 4-5 hours. Congestive heart failure/hepatic cirrhosis: >24 hours.
The terminal elimination half-life is approximately 12 hours in patients with normal renal function. In patients with moderate renal impairment (CrCl 30-50 mL/min), half-life is prolonged to 20-24 hours, necessitating dose adjustment.
Renal (10% unchanged) and hepatic metabolism (90%). Metabolites excreted in urine.
Renal excretion accounts for approximately 65% of the administered dose as unchanged drug, with an additional 20% as metabolites. Biliary/fecal excretion accounts for the remaining 15%, primarily as metabolites.
Category C
Category C
Bronchodilator
Bronchodilator